DUBLIN and LOUISVILLE, Ky., Oct.
2, 2015 /PRNewswire/ -- Allergan plc (NYSE: AGN), a
leading global specialty pharmaceutical company, today announced a
multi-year research collaboration with Humana Inc. (NYSE: HUM), one
of the nation's leading health and well-being companies, to explore
new ideas and ways to improve the health and well-being of
patients, members and their caregivers.
Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO
A main objective of the Allergan and Humana collaboration is to
study key issues and obtain a more comprehensive understanding of
opportunities for improvement in care delivery.
"In today's changing health care environment, it is important
for various stakeholders in the healthcare system to come together
to gain in-depth understanding of unmet needs and find solutions to
improve patient outcomes," said Gavin
Corcoran, MD, FACP, Chief Medical Officer, Allergan. "This
partnership aligns with our goal of leveraging real world data to
build evidence and conduct comparative effectiveness research in
collaboration with health care systems to better understand unmet
needs, the natural history of disease, and interventions that
improve both outcomes and the quality of care delivered to
patients."
"The partnership with Allergan reflects Humana's commitment to
improving health outcomes while reducing costs," said William Fleming, Pharm. D., President of Humana
Pharmacy Solutions. "Humana is always looking to collaborate where
we see an opportunity to make it easier for people to engage the
health care system and looks forward to focusing on these
initiatives with Allergan."
Under the terms of the agreement, Allergan and Humana will
initially focus on the following initiatives:
- Variety of Diseases – Improving health of patients with
central nervous system conditions, including Alzheimer's disease,
as well as glaucoma and other eye diseases with opportunities to
expand into other therapeutic areas as the collaboration
progresses.
- Patient/Caregiver Relationship – Obtain a clearer
picture of the attributes associated with caregiver burden from the
caregiver perspective, and how self-reported caregiver burden
relates to healthcare-related utilization and costs.
- Interventional Research – Conduct research based on
interventional practices and predictive analytics, with a focus on
treatment adherence, to ensure patients obtain the right
medications at the right time.
One of the collaboration's first projects focuses on Alzheimer's
patients' caregiver burden. Unlike caregiving for many terminal
illnesses, caregiving for Alzheimer's disease may persist for much
longer given that patients with Alzheimer's disease can live for
many years.
"Caregivers are vulnerable to health consequences as a result of
the chronic stressors associated with caring for a person with
Alzheimer's disease," said Roy
Beveridge, MD, Humana's Chief Medical Officer. "By working
together, Humana and Allergan can help close a gap in care by going
beyond the patient and focus on how to better understand and
support caregivers."
Caregiver burden in Alzheimer's disease tends to increase with
the progression of disease and corresponding increase in severity.
In addition, caregiver traits themselves may also be influential;
e.g., distance from patient, caregiver self-esteem, financial
status, and health status may affect the level of caregiver
burden.
Humana provides a wide variety of resources on caregiving. For
additional information, please contact
https://www.humana.com/individual-and-family-support/caregivers/.
About Allergan
Allergan plc (NYSE: AGN), headquartered
in Dublin, Ireland, is a unique,
global pharmaceutical company and a leader in a new industry
model—Growth Pharma. Allergan is focused on developing,
manufacturing, and commercializing innovative branded
pharmaceuticals, high-quality generic and over-the-counter
medicines, and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that
provide valuable treatments for the central nervous system, eye
care, medical aesthetics, gastroenterology, women's health,
urology, cardiovascular and anti-infective therapeutic categories,
and operates the world's third-largest global generics business,
providing patients around the globe with increased access to
affordable, high-quality medicines. Allergan is an industry leader
in research and development, with one of the broadest development
pipelines in the pharmaceutical industry and a leading position in
the submission of generic product applications globally.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, health care
providers, and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives.
For more information, visit Allergan's website at
www.allergan.com
About Humana
Humana Inc., headquartered in
Louisville, Ky., is a leading
health and well-being company focused on making it easy for people
to achieve their best health with clinical excellence through
coordinated care. The company's strategy integrates care delivery,
the member experience, and clinical and consumer insights to
encourage engagement, behavior change, proactive clinical outreach
and wellness for the millions of people Humana serves across the
country.
More information regarding Humana is available to investors via
the Investor Relations page of the company's web site at
www.humana.com, including copies of:
- Annual reports to stockholders
- Securities and Exchange Commission filings
- Most recent investor conference presentations
- Quarterly earnings news releases
- Replays of most recent earnings release conference calls
- Calendar of events (including upcoming earnings conference call
dates and times, as well as planned interaction with research
analysts and institutional investors)
- Corporate Governance information
Allergan Forward-Looking Statement
Statements
contained in this press release that refer to future events or
other non-historical facts are forward-looking statements that
reflect Allergan's current perspective of existing trends and
information as of the date of this release. Except as expressly
required by law, Allergan disclaims any intent or obligation to
update these forward-looking statements. Actual results may differ
materially from Allergan's current expectations depending upon a
number of factors affecting Allergan's business. These factors
include, among others, the risks associated with acquisition
transactions; the difficulty of predicting the timing or outcome of
FDA and other regulatory approvals or actions, if any; the impact
of competitive products and pricing; market acceptance of and
continued demand for Allergan's products; difficulties or delays in
manufacturing; and other risks and uncertainties detailed in
Allergan's periodic public filings with the Securities and Exchange
Commission, including but not limited to Allergan's Quarterly
Report on Form 10-Q for the quarter ended June 30, 2015 (such periodic public filings
having been filed under the "Allergan plc" or "Actavis plc" names)
and from time to time in Allergan's other investor communications .
Except as expressly required by law, Allergan disclaims any intent
or obligation to update these forward-looking statements.
CONTACTS:
Humana:
Alex Kepnes
Humana Corporate Communications
502-580-2990
akepnes@humana.com
Allergan:
Investors
Lisa DeFrancesco
862-261-7152
Lisa.defrancesco@allergan.com
Media
Mark Marmur
862-261-7558
Mark.marmur@allergan.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/allergan-and-humana-announce-research-partnership-to-improve-health-outcomes-300153282.html
SOURCE Allergan plc